RDY files June 2025 Form 6-K with SEC; details limited

Rhea-AI Filing Summary

Dr. Reddy’s Laboratories Limited (NYSE: RDY) filed a routine Form 6-K with the U.S. SEC dated 20 June 2025. The submission contains only the cover page, signature page and an index showing a single exhibit—Exhibit 99.1: “Intimation dated June 20, 2025.” The actual exhibit text and any related financial, operational or strategic information are not included in the material provided for review. Therefore, no financial results, guidance updates, transactions, regulatory actions or other material events can be assessed from this filing alone.

The filing confirms that RDY continues to report under Form 20-F for annual statements and that this 6-K is being furnished—not filed—for SEC purposes, preserving safe-harbor protections. The document was signed by Company Secretary K Randhir Singh.

Because the substantive Exhibit 99.1 content is unavailable, the investor impact of this 6-K cannot be determined based on the information supplied.

Insights

Financial Analyst

TL;DR: Routine 6-K cover; no financial data disclosed, therefore neutral investor impact.

This 6-K is essentially administrative. Without Exhibit 99.1, there are no revenue figures, margin updates, pipeline news or regulatory developments to evaluate. The filing merely affirms RDY’s ongoing compliance as a foreign private issuer and supplies a dated intimation whose content remains unseen. From a valuation perspective, the document offers no incremental information; price-sensitive investors can consider this filing non-material.

Corporate Governance Expert

TL;DR: Compliance-focused submission; satisfies disclosure rules but lacks substantive content.

The company meets SEC Rule 13a-16 obligations by furnishing this 6-K. Signature by the Company Secretary indicates proper internal authorization. However, absence of the exhibit content prevents assessment of governance issues such as board actions or policy changes. Overall, the filing is a standard procedural disclosure with no evident governance red flags.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

June, 2025

Commission File Number 1-15182

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x                                       Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨                                       No   x

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

EXHIBITS

Exhibit Number		Description of Exhibits
99.1		Intimation dated June 20, 2025

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date: June 20, 2025	By:	/s/ K Randhir Singh
		Name:	K Randhir Singh
		Title:	Company Secretary

3

FAQ

Why did Dr. Reddy’s Laboratories (RDY) file a Form 6-K on June 20, 2025?

The company furnished a routine 6-K to the SEC containing an index for Exhibit 99.1, titled “Intimation dated June 20, 2025.” No further details were provided.

Does the 6-K include financial results or earnings guidance for RDY?

No. The supplied material only shows the cover and signature pages; no financial or operational data are present.

Is the June 2025 6-K considered a material event for investors?

Based on the information provided, it appears administrative and non-material; the actual impact can’t be judged without Exhibit 99.1.

Who signed the Form 6-K for Dr. Reddy’s Laboratories?

Company Secretary K Randhir Singh signed the report on behalf of the registrant.